Efficacy and survival
acute lymphoblastic leukemia
DISEASE PROGRESSION, DISEASE, ACUTE LYMPHOBLASTIC LEUKEMIA
No patient achieved a CR or CRi. The best response was stable disease in 3 patients (19%). 6 (38%) patients had disease progression, whereas 7 (44%) patients were not evaluable because of early discontinuation of sapanisertib. Median follow‐up time for response was 22 days (range 3–64 days). Median survival was 62 days (51.0‐NA 95% CI), and all 6 patients with disease progression were deceased by day 155, reflecting the heavily pretreated cohort (Figure Overall survival for relapsed/refractory acute lymphoblastic leukemia patients treated with oral sapanisertib.